INT11858

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1981
Last Reported 2010
Negated 0
Speculated 2
Reported most in Abstract
Documents 39
Total Number 44
Disease Relevance 21.24
Pain Relevance 7.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Tbxa2r) plasma membrane (Tbxa2r) signal transducer activity (Tbxa2r)
Anatomy Link Frequency
platelets 17
macrophages 2
myocardium 2
plasma 1
PGE2 1
Tbxa2r (Mus musculus)
Pain Link Frequency Relevance Heat
adenocard 101 100.00 Very High Very High Very High
Angina 25 100.00 Very High Very High Very High
ischemia 27 99.92 Very High Very High Very High
cva 24 99.76 Very High Very High Very High
anesthesia 9 99.72 Very High Very High Very High
epidural 1 99.50 Very High Very High Very High
bradykinin 10 99.02 Very High Very High Very High
aspirin 455 98.92 Very High Very High Very High
cytokine 32 98.56 Very High Very High Very High
agonist 106 98.18 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 40 100.00 Very High Very High Very High
Cv General 2 Under Development 16 99.92 Very High Very High Very High
Coronary Vasospasm 7 99.68 Very High Very High Very High
Increased Venous Pressure Under Development 65 99.66 Very High Very High Very High
Cv Unclassified Under Development 26 99.32 Very High Very High Very High
Thrombosis 174 99.26 Very High Very High Very High
Coronary Heart Disease 15 99.10 Very High Very High Very High
Injury 49 98.84 Very High Very High Very High
Ulcers 1 98.68 Very High Very High Very High
Lifespan 2 98.50 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Bradykinin-induced bronchoconstriction is due, in part, to release of TXA2 and prostaglandins.
Localization (release) of TXA2 associated with bradykinin
1) Confidence 0.80 Published 1982 Journal Pharmacology Section Abstract Doc Link 6806831 Disease Relevance 0.24 Pain Relevance 0.37
Strong stimuli for TxA2 release from these tissues may initiate ulcer, pulmonary hypertension, bronchoconstriction, and renal vasoconstriction.
Localization (release) of TxA2 associated with hypertension, ulcers and increased venous pressure under development
2) Confidence 0.79 Published 1987 Journal Fed. Proc. Section Abstract Doc Link 2948837 Disease Relevance 0.87 Pain Relevance 0.13
Our previous studies indicate that the blockade of the sympathetic nervous system by spinal anesthesia or epidural anesthesia inhibits the release of TXA2 induced by limb ischemia with thigh tourniquet in patients with lower limb surgery.
Localization (release) of TXA2 in sympathetic nervous system associated with anesthesia, ischemia and epidural
3) Confidence 0.67 Published 1989 Journal Masui Section Abstract Doc Link 2733138 Disease Relevance 0.17 Pain Relevance 0.34
TxA2 is unlikely to cause vasotonic angina, but it may be released during coronary vasospasm.
Localization (released) of TxA2 associated with angina and coronary vasospasm
4) Confidence 0.64 Published 1981 Journal N. Engl. J. Med. Section Abstract Doc Link 7010173 Disease Relevance 0.94 Pain Relevance 0.55
As both prostaglandin I2 and acetylcholine-induced EDRF also inhibit platelet aggregation, endothelial injury and loss of these factors may predispose to vasospasm precipitated by release of platelet-derived mediators such as thromboxane A2 (TXA2) and 5-hydroxytryptamine.
Localization (release) of TXA2 in platelet associated with injury and increased venous pressure under development
5) Confidence 0.60 Published 1987 Journal Fed. Proc. Section Abstract Doc Link 3100342 Disease Relevance 0.46 Pain Relevance 0.14
As both prostaglandin I2 and acetylcholine-induced EDRF also inhibit platelet aggregation, endothelial injury and loss of these factors may predispose to vasospasm precipitated by release of platelet-derived mediators such as thromboxane A2 (TXA2) and 5-hydroxytryptamine.
Localization (release) of thromboxane A2 in platelet associated with injury and increased venous pressure under development
6) Confidence 0.60 Published 1987 Journal Fed. Proc. Section Abstract Doc Link 3100342 Disease Relevance 0.45 Pain Relevance 0.14
H2O2 exposure induces translocation of functional thromboxane receptor to the plasma membrane
Localization (translocation) of thromboxane receptor in plasma
7) Confidence 0.57 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2939892 Disease Relevance 0 Pain Relevance 0.05
We conclude that group III and IV afferent fibers originating from the skeletal muscle of the hindlimb are stimulated by TxA2 and that the release of TxA2 in skeletal muscle could evoke cardiorespiratory reflexes known to be activated by stimulation of these afferent nerves.
Localization (release) of TxA2 in hindlimb
8) Confidence 0.56 Published 1997 Journal Brain Res. Section Abstract Doc Link 9030430 Disease Relevance 0 Pain Relevance 0.15
Excretion of thromboxane A2 and prostacyclin metabolites during treadmill exercise in patients with intermittent claudication.
Localization (Excretion) of thromboxane A2 associated with restless leg syndrome
9) Confidence 0.55 Published 1988 Journal Clin Physiol Section Title Doc Link 3402185 Disease Relevance 0.51 Pain Relevance 0.25
The other studies have stressed that coronary spasm induced by TxA2 released from activated platelet is an important mechanism underlying the myocardial injury caused by activated platelet [10,11].
Localization (released) of TxA2 in platelet associated with injury and cva
10) Confidence 0.48 Published 2010 Journal Korean Journal of Anesthesiology Section Body Doc Link PMC2872863 Disease Relevance 0.54 Pain Relevance 0.28
The balance between thromboxane A2 (TXA2), a proaggregatory agent released from platelets and PGI2 may have a role in the genesis and management of angina and myocardial infarction.
Localization (released) of thromboxane A2 in platelets associated with angina and myocardial infarction
11) Confidence 0.48 Published 1985 Journal Can J Cardiol Section Abstract Doc Link 3850765 Disease Relevance 0.70 Pain Relevance 0.19
The balance between thromboxane A2 (TXA2), a proaggregatory agent released from platelets and PGI2 may have a role in the genesis and management of angina and myocardial infarction.
Localization (released) of TXA2 in platelets associated with angina and myocardial infarction
12) Confidence 0.48 Published 1985 Journal Can J Cardiol Section Abstract Doc Link 3850765 Disease Relevance 0.70 Pain Relevance 0.19
The release of vasoconstrictor substances, such as thromboxane A2 (TXA2) and platelet activating factor (PAF) by macrophages, which are the predominant inflammatory cells, was proposed to cause transient ischemia and myocytolytic necrosis [8].
Spec (proposed) Localization (release) of TXA2 in macrophages associated with necrosis, inflammation and ischemia
13) Confidence 0.44 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 1.51 Pain Relevance 0.20
The release of vasoconstrictor substances, such as thromboxane A2 (TXA2) and platelet activating factor (PAF) by macrophages, which are the predominant inflammatory cells, was proposed to cause transient ischemia and myocytolytic necrosis [8].
Spec (proposed) Localization (release) of thromboxane A2 in macrophages associated with necrosis, inflammation and ischemia
14) Confidence 0.44 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 1.51 Pain Relevance 0.20
TXA2 release was markedly increased, as demonstrated by contraction of rabbit aortic strips perfused with coronary venous blood draining the ischemic myocardium, and by increased release of radioimmunologically assayable TXB2.
Localization (release) of TXA2 in myocardium
15) Confidence 0.40 Published 1984 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 6202970 Disease Relevance 0.57 Pain Relevance 0
The effect might be related to improvement of coronary circulation and inhibition of release of vasoactive substances, including TXA2, from the ischemic myocardium.
Localization (release) of TXA2 in myocardium
16) Confidence 0.40 Published 1984 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 6202970 Disease Relevance 0.44 Pain Relevance 0
In fact, Davì et al (1990) showed that urinary thromboxane B2 (TxB2), a stable metabolite of TxA2, was significantly higher in patients with type 2 diabetes than in controls.
Localization (metabolite) of TxA2 associated with diabetes mellitus
17) Confidence 0.39 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0.49 Pain Relevance 0.20
Thromboxane A2 (TxA2), released by aggregating platelets, has been proposed as a potential mediator of coronary vasospasm.
Localization (released) of TxA2 in platelets associated with coronary vasospasm
18) Confidence 0.37 Published 1982 Journal Circulation Section Abstract Doc Link 7116586 Disease Relevance 0.59 Pain Relevance 0.26
Thromboxane A2 (TxA2), released by aggregating platelets, has been proposed as a potential mediator of coronary vasospasm.
Localization (released) of Thromboxane A2 in platelets associated with coronary vasospasm
19) Confidence 0.37 Published 1982 Journal Circulation Section Abstract Doc Link 7116586 Disease Relevance 0.59 Pain Relevance 0.26
To study the effects of propranolol on platelets, we measured plasma beta thromboglobulin and plasma thromboxane B2 (TXB2, stable metabolite of TXA2) levels by radioimmunoassay as indexes of platelet alpha-granule and TXA2 release, respectively.
Localization (release) of TXA2 in platelets
20) Confidence 0.37 Published 1982 Journal Circulation Section Abstract Doc Link 6216027 Disease Relevance 0.26 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox